Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Not Applicable
Recruiting
- Conditions
- Transfusion-dependent Beta-Thalassemia
- Interventions
- Genetic: KL003 cell injection Drug Product
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 3
- Registration Number
- NCT06219239
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
Phase 1
Recruiting
- Conditions
- CD19 CAR-T Cell InfusionAutoimmune Hemolytic Anemia
- Interventions
- Biological: ThisCART19A
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 13
- Registration Number
- NCT06212154
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Not Applicable
Recruiting
- Conditions
- Transplant-Related Disorder
- Interventions
- Behavioral: Health monitoring and regular return follow-up reminders
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 456
- Registration Number
- NCT06208137
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
Phase 2
Active, not recruiting
- Conditions
- Immune ThrombocytopeniaTreatment
- Interventions
- Drug: Placebo Injection
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 45
- Registration Number
- NCT06199089
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Phase 2
Recruiting
- Conditions
- Immune ThrombocytopeniaTreatment
- Interventions
- Drug: Anti-CD38 antibody Injection
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 20
- Registration Number
- NCT06168851
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: DVRd
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 40
- Registration Number
- NCT06158269
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
Phase 2
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: MCBC regimenDrug: Bu/Cy regimen
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-15
- Target Recruit Count
- 237
- Registration Number
- NCT06133556
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Recruiting
- Conditions
- C-KIT Mutation
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 50
- Registration Number
- NCT06116318
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Recruiting
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Other: data collection
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 500
- Registration Number
- NCT06107582
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, China
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Recruiting
- Conditions
- Thrombotic MicroangiopathiesHematopoietic Stem Cell Transplantation
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 300
- Registration Number
- NCT06102694
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath